loader
Please Wait
Applying Filters...
menu
    • menu

    List of Certificates of Suitability (CEPs) for Rivastigmine Active Pharmaceutical Ingredient (API) issued by the EDQM. Original Data: EDQM Database

    Client Email Product
    2024 US Elections: Harris, Trump differ on abortion rights, ACA, public health spends; agree on need to cut drug prices

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Aug 2024: Otsuka buys Jnana, Lilly’s market cap gains by over US$ 108 bn post new guidance

    Stock Recap
    #PipelineProspector

    Menu

    Rivastigmine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 3,038Xls download

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Certificate Holder Certificate No. Substance Issue Date Status Type End Date Substance No.
    26/09/2024 Interquim SA
    Spain
    		 Interquim, S.A. Sant Cugat Del Vallès ES R1-CEP 2013-354 - Rev 00 Rivastigmine 2020-01-23 Valid Chemical 2629
    26/09/2024 Alembic Pharmaceuticals Limited
    India
    		 ALEMBIC PHARMACEUTICALS LIMITED Vadodara IN R1-CEP 2015-039 - Rev 00 Rivastigmine 2020-11-24 Valid Chemical 2629